drugset / Trial / NCT00978913
Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The primary aim of this study is to evaluate the toxicity of the vaccine and the combination of the vaccine and Cyclophosphamide, and to evaluate the immune response induced by the vaccine. The secondary aim is to investigate the clinical tumour response and duration of tumour and immune response.
Timeline
- Start
- 2009-09
- Primary completion
- 2013-08
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC vaccine | Vaccine | 1e+06 cells | Other |
| Background | Cyclophosphamide | Other / unclassified | 50 mg | — |